Abstract
Preterm birth (PTB) is a leading cause of neonatal mortality and morbidity worldwide, and surviving infants are at increased risks of lifelong complications. PTB has been firmly linked to inflammation regardless of infection, specific aetiology or timing of birth. Deleterious inflammation is observed in maternal and fetal tissue, and correlates with the severity of perinatal complications. At present, PTB is treated with tocolytics as though it is exclusively a myometrial contractile disorder. These agents do not address underlying inflammatory processes and are thus vastly ineffective at improving neonatal outcomes. Of all inflammatory mediators, IL-1 is central to the pathophysiology of PTB and most adverse neonatal outcomes. We thus present herein a review of the various effects of IL-1 in utero, with a brief overview of its mechanism of action. We then discuss the potential of different IL-1-targeting agents based on pre-clinical testing in relevant models of PTB and neonatal inflammatory injuries.
Keywords: Interleukin-1, preterm labor, preterm birth, inflammation, neonatal injuries, neonatal mortality.
Related Journals
Related Books
Endocannabinoids: Molecular, Pharmacological, Behavioral and Clinical Features
Ricin Toxin
The Pharmaceutical Scientist Guide to Solution Kinetic Models Mathematical Description and Applications
Solubility, Delivery and ADME Problems of Drugs and Drug-Candidates
Biologically Active Natural Products from Asia and Africa: A Selection of Topics
Postbiotics: Science, Technology and Applications
Nanotechnology Driven Herbal Medicine for Burns: From Concept to Application
Medical Applications of Beta-Glucan
39
4
1
2